Welcome to our dedicated page for Organon & Co. news (Ticker: OGN), a resource for investors and traders seeking the latest updates and insights on Organon & Co. stock.
Organon & Co. (OGN) is a science-based global pharmaceutical company dedicated to developing and delivering essential health solutions. Founded in Oss, the Netherlands, Organon originally gained fame for pioneering the birth control pill, which revolutionized women's health. Over the years, the company expanded significantly and was acquired by Schering-Plough, and later by Merck, continuing its legacy as MSD in the Netherlands.
Today, Organon operates with a robust portfolio comprising women's health, biosimilars, and established medicines. The company focuses on providing prescription therapies that address a wide range of health needs, particularly in women's health. Organon's product offerings include innovations in contraception, fertility treatments, and menopause management.
In addition to women's health, Organon is committed to advancing the field of biosimilars - biologically similar products to existing branded drugs that promise to enhance patient access to key treatments. The company's established brands, which include a variety of well-known medications, continue to be a core revenue driver. Geographically, Organon derives most of its revenue from Europe and Canada, followed by the United States, and then the Asia Pacific and Japan regions.
Organon remains at the forefront of pharmaceutical innovation, driven by a mission to improve health outcomes globally. The company's strategic partnerships and continued investment in research and development reflect its commitment to addressing some of the most pressing health challenges of our time.
The FDA has extended its review period for VTAMA® (tapinarof) cream, 1% for atopic dermatitis treatment in adults and children aged 2 and older by three months. The new target date is March 12, 2025, moved from December 12, 2024. The extension follows FDA's request for final datasets from the long-term extension study. The FDA has not raised safety, efficacy, or approvability concerns. Organon projects $125 million in VTAMA revenue for 2025, with an approximate 75 basis point headwind to Adjusted EBITDA margin.
Organon (OGN) reported strong Q3 2024 results with revenue of $1.582 billion, up 4% as-reported and 5% at constant currency. The company achieved net income of $359 million and diluted EPS of $1.38. Women's Health revenue grew 5%, Biosimilars increased 16%, and Established Brands rose 2%. The company narrowed its full-year 2024 revenue guidance to $6.375-$6.425 billion and revised Adjusted EBITDA margin to 30.0-31.0%. Nexplanon showed strong performance with 11% growth, positioning it to deliver $1 billion in revenue next year. The Board declared a quarterly dividend of $0.28 per share.
Shanghai Henlius Biotech and Organon (NYSE: OGN) announced the US FDA's acceptance of their Biologics License Application (BLA) for HLX14, a biosimilar candidate of PROLIA/XGEVA (denosumab). The application is supported by comprehensive head-to-head studies, including analytical comparisons and two clinical trials. Under a 2022 license agreement, Organon holds exclusive commercialization rights for HLX14 in the US, EU, and Canada, excluding China. The clinical program included a phase 1 study in healthy males and a phase 3 trial in postmenopausal women with high-risk osteoporosis.
Organon (NYSE: OGN) has completed its acquisition of Dermavant Sciences from Roivant, expanding its dermatology portfolio with VTAMA® (tapinarof) cream. VTAMA is a novel nonbiologic, non-steroidal topical therapy FDA-approved for plaque psoriasis in adults, with no safety label warnings or use restrictions. The FDA is reviewing VTAMA for atopic dermatitis treatment in adults and children, with a decision expected in Q4 2024. The acquisition strengthens Organon's dermatology capabilities, particularly in treating chronic inflammatory skin conditions that affect millions globally, with psoriasis and atopic dermatitis having significant impact on quality of life.
Organon (NYSE: OGN), a global healthcare company focusing on women's health, will release its third quarter 2024 financial results on October 31, 2024, before a webcast and conference call at 8:30 a.m. EDT. The company anticipates recording $51 million in milestone expenses for Q3 2024, impacting both GAAP and non-GAAP earnings per share by approximately $0.16. Of this, $50 million relates to a denosumab biosimilar candidate progressing under an agreement with Shanghai Henlius Biotech, Inc.
Organon notes that IPR&D and milestones are not included in their financial guidance due to uncertainty in timing. The Q3 2024 results are preliminary and subject to finalization. Interested parties can access the live call via webcast on Organon's website, with a replay available approximately two hours after the event.
Shanghai Henlius Biotech and Organon (NYSE: OGN) have announced that their phase 3 comparative clinical trial for the investigational Perjeta® (pertuzumab) biosimilar HLX11 has met its primary endpoint. The study compared HLX11 with reference Perjeta® as a neoadjuvant therapy in patients with HER2-positive, HR-negative early or locally advanced breast cancer.
The trial (NCT05346224) was a multicenter, randomized, double-blind, parallel-controlled study. Patients received either HLX11 or reference Perjeta® combined with trastuzumab and docetaxel. The primary endpoint was the total pathological complete response (tpCR) rate assessed by an Independent Review Committee. Secondary endpoints included various response rates, survival measures, safety, pharmacokinetics, and immunogenicity.
In 2022, Henlius granted Organon exclusive global commercialization rights for HLX11, except for China. Pertuzumab is approved in various countries for neoadjuvant, first-line, and adjuvant treatment of certain advanced HER2-positive breast cancers.
Organon (NYSE: OGN) has agreed to acquire Dermavant Sciences , a Roivant company, for up to $1.2 billion. The deal includes Dermavant's VTAMA® (tapinarof) cream, a novel, non-steroidal topical therapy for plaque psoriasis in adults. VTAMA is also under FDA review for atopic dermatitis treatment. The acquisition aims to extend Organon's international dermatology capabilities to the U.S.
Key points:
- Upfront payment of $175 million
- $75 million milestone payment upon regulatory approval for atopic dermatitis
- Up to $950 million for commercial milestones
- Tiered royalties on net sales
- Expected closing in Q4 2024
- Transaction subject to Hart-Scott-Rodino Antitrust Improvements Act review
Organon (NYSE: OGN) has expanded its agreement with Eli Lilly to become the sole distributor and promoter for the migraine medicine Emgality® (galcanezumab) in 11 additional markets. This builds on Organon's existing role as distributor in Europe since February 2024. Emgality is a CGRP antagonist for migraine prevention in adults and, in some markets, for episodic cluster headache treatment.
The expansion highlights Organon's focus on women's health, as women are three times more likely to experience migraines than men. The agreement includes an upfront payment of $22.5 million to Lilly, plus sales-based milestone payments. Lilly will remain the marketing authorization holder and manufacturer of Emgality.
Organon (NYSE: OGN) reported Q2 2024 revenue of $1.607 billion, flat year-over-year but up 2% at constant currency. Diluted EPS was $0.75, while non-GAAP Adjusted diluted EPS was $1.12. The company narrowed its full-year 2024 revenue guidance to $6.250-$6.450 billion. Key highlights:
- Women's Health revenue grew 3%, driven by 13% growth in Nexplanon
- Biosimilars revenue increased 22%, boosted by Hadlima's U.S. launch
- Established Brands revenue declined 1% ex-FX
- Gross margin was 58.4% (62.0% non-GAAP Adjusted)
- Net income was $195 million, down 19% year-over-year
- Adjusted EBITDA was $513 million with a 31.9% margin
The company declared a quarterly dividend of $0.28 per share.
Organon (NYSE: OGN) will announce its Q2 2024 financial results on August 6, 2024. The company's webcast and conference call are scheduled for 8:30 a.m. EDT. Organon estimates a $15 million milestone expense in the second quarter, impacting both GAAP and non-GAAP EPS by approximately $0.05. These expenses stem from collaborations with Cirqle Biomedical and Shanghai Henlius Biotech. The company notes that these milestones are not included in their May 2, 2024, financial guidance due to forecasting uncertainties. Final results are pending and may differ from estimates.
Interested parties can access the live webcast on Organon's website, with a replay available two hours post-event. Institutional investors and analysts need to pre-register to participate in the call.
FAQ
What is the current stock price of Organon & Co. (OGN)?
What is the market cap of Organon & Co. (OGN)?
What is Organon & Co. known for?
What are the main product areas of Organon & Co.?
Where does Organon & Co. generate most of its revenue?
Who previously acquired Organon & Co.?
What types of products does Organon offer in women's health?
What are biosimilars?
How does Organon & Co. contribute to global health?
Has Organon & Co. been involved in any recent significant projects or initiatives?
What is the history of Organon & Co. in the Netherlands?
What is the significance of Organon's established brands?
